Outcome of Intravitreal Dexamethasone Implant Use in Uveitic Eyes Undergoing Pars Plana Vitrectomy Surgery.

Autor:	Kirkland, Kyle A., Uwaydat, Sami H., Siddiqui, Mohammad Z., Chancellor, John R., Soliman, Mohamed K., Kurup, Shree, Sallam, Ahmed B.
Předmět:	PARS plana VITRECTOMY DEXAMETHASONE INTRAOCULAR pressure VISUAL acuity SURGERY
Zdroj:	Ocular Immunology & Inflammation; 2021, Vol. 29 Issue 6, p1126-1131, 6p
Abstrakt:	Purpose: To report the outcomes in eyes with noninfectious uveitis receiving dexamethasone implant at the time of pars plana vitrectomy (PPV). Methods: Retrospective analysis of visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), and central subfield thickness (CST) at baseline and follow-up visits. Results: Fourteen eyes received dexamethasone implant at the time of PPV. The CST was improved from 469 ± 182 µm at baseline to 320 ± 60 at 6 months (p =.0112) and 295 ± 46 at 12 months (p =.0728). Vitritis only recurred in 2 eyes at 6 months (18.2%) and 1 eye at 12 months (14.3%). The probability of VA improvement of ≥0.3 logMAR was 57% at 6 months and 66% at 12 months. Therapy for IOP rise was initiated in 6 eyes (42.9%). Conclusions: Local delivery of dexamethasone implant with PPV is a feasible method to counteract postoperative inflammation and macular thickening. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.